Molecular Pathology of Large Cell Carcinoma and Its Precursors

  • Jennifer A. Eleazar
  • Alain C. Borczuk
Part of the Molecular Pathology Library book series (MPLB, volume 1)


The classification of lung carcinomas remains primarily morphologic with individual instances in which immunohistochemistry can serve as an adjunctive test. In the case of large cell carcinoma, the current WHO classification system remains partly one of exclusion; that is, the tumor should lack morphologic features that are generally associated with small cell lung carcinoma (SCLC), adenocarcinoma, and squamous cell carcinoma (Figure 27.1A).1 For example, a poorly differentiated carcinoma with demonstrable mucin (more than five mucin-positive cells in at least two high-power fields) by special stains would be designated as solid adenocarcinoma with mucin rather than as large cell carcinoma.
Figure 27.1

Histologic features of large cell carcinomas. (A) Large cell carcinoma. (B) Large cell neuroendocrine carcinoma, with inset showing synaptophysin immunoreactivity. (C) Basaloid carcinoma. (D) Lymphoepithelioma-like carcinoma. (E) Large cell carcinoma with rhabdoid phenotype. (Hematoxylin and eosin, original magnification, ×150).


Squamous Cell Carcinoma Epidermal Growth Factor Receptor Mutation Kras2 Mutation Neuroendocrine Carcinoma Small Cell Lung Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.Google Scholar
  2. 2.
    Hammar SP, Bolen JW, Bockus D, et al. Ultrastructural and immunohistochemical features of common lung tumors: an overview. Ultrastruct Pathol 1985;9(3–4):283–318.CrossRefPubMedGoogle Scholar
  3. 3.
    Kodama T, Shimosato Y, Koide T, et al. Large cell carcinoma of the lung—ultrastructural and immunohistochemical studies. Jpn J Clin Oncol 1985;15(2):431–441.PubMedGoogle Scholar
  4. 4.
    Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15(6):529–553.PubMedGoogle Scholar
  5. 5.
    Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 1992;23(9):993–1003.CrossRefPubMedGoogle Scholar
  6. 6.
    Moro D, Brichon PY, Brambilla E, et al. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994;73(11):2734–2739.CrossRefPubMedGoogle Scholar
  7. 7.
    Chan JK, Hui PK, Tsang WY, et al. Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer 1995;76(3):413–422.CrossRefPubMedGoogle Scholar
  8. 8.
    Butler AE, Colby TV, Weiss L, Lombard C. Lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol 1989;13(8):632–639.PubMedCrossRefGoogle Scholar
  9. 9.
    Castro CY, Ostrowski ML, Barrios R, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol 2001;32(8):863–872.CrossRefPubMedGoogle Scholar
  10. 10.
    Chang YL, Wu CT, Shih JY, Lee YC. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol 2002;26(6):715–723.CrossRefPubMedGoogle Scholar
  11. 11.
    Cavazza A, Colby TV, Tsokos M, et al. Lung tumors with a rhabdoid phenotype. Am J Clin Pathol 1996;105(2):182–188.PubMedGoogle Scholar
  12. 12.
    Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001;91(11):1992–2000.CrossRefPubMedGoogle Scholar
  13. 13.
    Ishida T, Kaneko S, Tateishi M, et al. Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. Am J Clin Pathol 1990;93(2):176–182.PubMedGoogle Scholar
  14. 14.
    Schulte MA, Ramzy I, Greenberg SD. Immunocytochemical characterization of large-cell carcinomas of the lung. Role, limitations and technical considerations. Acta Cytol 1991;35(2):175–80.PubMedGoogle Scholar
  15. 15.
    Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000;31(8):980–987.CrossRefPubMedGoogle Scholar
  16. 16.
    Pomplun S, Wotherspoon AC, Shah G, et al. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. Histopathology 2002;40(2):152–158.CrossRefPubMedGoogle Scholar
  17. 17.
    Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122(6):884–893.CrossRefPubMedGoogle Scholar
  18. 18.
    Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204(1):101–109.CrossRefPubMedGoogle Scholar
  19. 19.
    Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32(9):918–925.CrossRefPubMedGoogle Scholar
  20. 20.
    Lantuejoul S, Moro D, Michalides RJ, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998;22(10):1267–1276.CrossRefPubMedGoogle Scholar
  21. 21.
    Sturm N, Rossi G, Lantuejoul S, et al. 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology 2003;42(2):156–166.CrossRefPubMedGoogle Scholar
  22. 22.
    Peng WX, Sano T, Oyama T, et al. Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma. Lung Cancer 2005;47(2):225–233.CrossRefPubMedGoogle Scholar
  23. 23.
    Whitsett JA, Glasser SW. Regulation of surfactant protein gene transcription. Biochim Biophys Acta 1998;1408(2–3):303–311.PubMedGoogle Scholar
  24. 24.
    Linnoila RI, Jensen SM, Steinberg SM, et al. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol 1992;97(2):233–243.PubMedGoogle Scholar
  25. 25.
    Uzaslan E, Ebsen M, Stuempel T, et al. Surfactant protein A detection in large cell carcinoma of the lung. Appl Immunohistochem Mol Morphol 2006;14(1):88–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125(2):228–231.PubMedGoogle Scholar
  27. 27.
    Morbini P, Riboni R, Tomaselli S, et al. Eber-and LMP-1-expressing pulmonary lymphoepithelioma-like carcinoma in a Caucasian patient. Hum Pathol 2003;34(6):623–625.CrossRefPubMedGoogle Scholar
  28. 28.
    Han AJ, Xiong M, Gu YY, Lin SX. Lymphoepithelioma-like carcinoma of the lung with a better prognosis. A clinicopathologic study of 32 cases. Am J Clin Pathol 2001;115(6):841–8450.CrossRefPubMedGoogle Scholar
  29. 29.
    Tamboli P, Toprani TH, Amin MB, et al. Carcinoma of lung with rhabdoid features. Hum Pathol 2004;35(1):8–13.CrossRefPubMedGoogle Scholar
  30. 30.
    Shimazaki H, Aida S, Sato M, et al. Lung carcinoma with rhabdoid cells: a clinicopathological study and survival analysis of 14 cases. Histopathology 2001;38(5):425–434.CrossRefPubMedGoogle Scholar
  31. 31.
    Fleming MV, Guinee DG Jr, Chu WS, et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol 1998;29(1):60–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen FF, Yan JJ, Lai WW, et al. Epstein-Barr virusassociated nonsmall cell lung carcinoma: undifferentiated “lymphoepithelioma-like“ carcinoma as a distinct entity with better prognosis. Cancer 1998;82(12):2334–2342CrossRefPubMedGoogle Scholar
  33. 33.
    Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15(1):28–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Araki K, Ishii G, Yokose T, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40(2):173–180.CrossRefPubMedGoogle Scholar
  35. 35.
    Maruyama R, Sugio K, Yoshino I, et al. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004;100(7):1472–1477.CrossRefPubMedGoogle Scholar
  36. 36.
    Igarashi T, Jiang SX, Kameya T, et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004;17(10):1259–1267.CrossRefPubMedGoogle Scholar
  37. 37.
    Beasley MB, Lantuejoul S, Abbondanzo S, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34(2):136–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56(15):3415–3420.PubMedGoogle Scholar
  39. 39.
    Hiroshima K, Iyoda A, Shibuya K, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 2004;100(6):1190–1198.CrossRefPubMedGoogle Scholar
  40. 40.
    Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in nonsmall cell lung carcinoma and their clinical significance. J Pathol 1999;188(4):351–360.CrossRefPubMedGoogle Scholar
  41. 41.
    Lorenz J, Friedberg T, Paulus R, et al. Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance. Clin Invest 1994;72(2):156–163.CrossRefGoogle Scholar
  42. 42.
    Eerola AK, Ruokolainen H, Soini Y, et al. Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. Pathol Oncol Res 1999;5(3):179–186.CrossRefPubMedGoogle Scholar
  43. 43.
    Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in nonsmall-cell lung carcinoma. N Engl J Med 1993;329(10):690–694.CrossRefPubMedGoogle Scholar
  44. 44.
    Ab’ Saber AM, Massoni Neto LM, Bianchi CP, et al. Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg 2004;77(6):1883–1890.CrossRefGoogle Scholar
  45. 45.
    Johansson M, Dietrich C, Mandahl N, et al. Karyotypic characterization of bronchial large cell carcinomas. Int J Cancer 1994;57(4):463–467.CrossRefPubMedGoogle Scholar
  46. 46.
    Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002;21(45):6877–6883.CrossRefPubMedGoogle Scholar
  47. 47.
    Bjorkqvist AM, Tammilehto L, Nordling S, et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 1998;77(2):260–269.PubMedGoogle Scholar
  48. 48.
    Luk C, Tsao MS, Bayani J, et al. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001;125(2):87–99.CrossRefPubMedGoogle Scholar
  49. 49.
    Weston A, Willey JC, Modali R, et al. Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 1989;86(13):5099–5103.CrossRefPubMedGoogle Scholar
  50. 50.
    Li J, Zhang Z, Dai Z, et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 2003;22(8):1243–1246.CrossRefPubMedGoogle Scholar
  51. 51.
    Ullmann R, Petzmann S, Sharma A, et al. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 2001;32(10):1059–1063.CrossRefPubMedGoogle Scholar
  52. 52.
    Shin JH, Kang SM, Kim YS, et al. Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. Chest 2005;128(4):2999–3003.CrossRefPubMedGoogle Scholar
  53. 53.
    Mitani S, Kamata H, Fujiwara M, et al. Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction. Clin Exp Med 2001;1(2):105–111.CrossRefPubMedGoogle Scholar
  54. 54.
    Haggerty TJ, Zeller KI, Osthus RC, et al. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci USA 2003;100(9):5313–5318.CrossRefPubMedGoogle Scholar
  55. 55.
    Borczuk AC, Shah L, Pearson GD, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170(2):167–174.CrossRefPubMedGoogle Scholar
  56. 56.
    Liu D, Huang CL, Kameyama K, et al. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer 2002;94(8):2239–2247.CrossRefPubMedGoogle Scholar
  57. 57.
    Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8(7):625–634.PubMedGoogle Scholar
  58. 58.
    Jarmalaite S, Kannio A, Anttila S, et al. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003;106(6):913–918.CrossRefPubMedGoogle Scholar
  59. 59.
    Tanaka H, Fujii Y, Hirabayashi H, et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998;79(2):111–115.CrossRefPubMedGoogle Scholar
  60. 60.
    Reissmann PT, Koga H, Figlin RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999;125(2):61–70.CrossRefPubMedGoogle Scholar
  61. 61.
    Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52(9 Suppl):2665s–2669s.PubMedGoogle Scholar
  62. 62.
    Li J, Zhang Z, Dai Z, et al. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia 2003;5(4):362–366.PubMedGoogle Scholar
  63. 63.
    Przygodzki RM, Koss MN, Moran CA, et al. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. Am J Clin Pathol 1996;106(4):487–492.PubMedGoogle Scholar
  64. 64.
    Pelosi G, Scarpa A, Manzotti M, et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004;17(5):538–546.CrossRefPubMedGoogle Scholar
  65. 65.
    Debelenko LV, Swalwell JI, Kelley MJ, et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000;28(1):58–65.CrossRefPubMedGoogle Scholar
  66. 66.
    Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005;23(34):8774–8785.CrossRefPubMedGoogle Scholar
  67. 67.
    Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85(3):600–607.CrossRefPubMedGoogle Scholar
  68. 68.
    Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148(5):1531–1541.PubMedGoogle Scholar
  69. 69.
    Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12(5):1647–1653.CrossRefPubMedGoogle Scholar
  70. 70.
    Wong MP, Cheung KN, Yuen ST, et al. Monocyte chemoattractant protein-1 (MCP-1) expression in primary lymphoepithelioma-like carcinomas (LELCs) of the lung. J Pathol 1998;186(4):372–377.CrossRefPubMedGoogle Scholar
  71. 71.
    Pizzoferrato E, Liu Y, Gambotto A, et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res 2004;64(22):8381–8388.CrossRefPubMedGoogle Scholar
  72. 72.
    Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000;10(2):73–81.CrossRefPubMedGoogle Scholar
  73. 73.
    Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected nonsmall cell lung cancer. Clin Cancer Res 2003;9(13):4695–4704.PubMedGoogle Scholar
  74. 74.
    Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98(24):13784–13789.CrossRefPubMedGoogle Scholar
  75. 75.
    Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363(9411):775–781.CrossRefPubMedGoogle Scholar
  76. 76.
    Takeuchi T, Tomida S, Yatabe Y, et al. Expression profiledefined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24(11):1679–1688.CrossRefPubMedGoogle Scholar
  77. 77.
    Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classifi-cation of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99(19):12357–12362.CrossRefPubMedGoogle Scholar
  78. 78.
    Borczuk AC, Gorenstein L, Walter KL, et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003;163(5):1949–1960.PubMedGoogle Scholar
  79. 79.
    Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362(9382):433–439.CrossRefPubMedGoogle Scholar
  80. 80.
    Li LS, Kim H, Rhee H, et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004;4(11):3394–3400.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Jennifer A. Eleazar
    • 1
  • Alain C. Borczuk
    • 2
  1. 1.Department of Clinical PathologyColumbia University Medical CenterNew YorkUSA
  2. 2.Department of PathologyColumbia University Medical CenterNew YorkUSA

Personalised recommendations